Risk of natalizumab-associated progressive multifocal leukoencephalopathy. - Wikidata - wikimedia - TriplyDB

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

http://www.wikidata.org/entity/Q34275329

about

Human polyomavirus reactivation: disease pathogenesis and treatment approaches Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease Vedolizumab for induction and maintenance of remission in Crohn’s disease Vedolizumab for induction and maintenance of remission in ulcerative colitis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Advances in the development of new biologics in inflammatory bowel disease Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices Progressive Multifocal Leukoencephalopathy Review of vedolizumab for the treatment of ulcerative colitis Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Progressive multifocal leukoencephalopathy: current treatment options and future perspectives Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group γδ T Cells and NK Cells - Distinct Pathogenic Roles as Innate-Like Immune Cells in CNS Autoimmunity Migration and pathogenicity of CD8 T cells in central nervous system diseases Immune interventions in stroke Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Multiple sclerosis-a quiet revolution Role of immunosuppressive therapy for the treatment of multiple sclerosis JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory responses in hypoxic ischemic encephalopathy An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations Biomarkers of therapeutic response in multiple sclerosis: current status Progressive multifocal leukoencephalopathy: new concepts Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Personalized medicine in multiple sclerosis: hope or reality?Progressive Multifocal Leukoencephalopathy-Associated Mutations in the JC Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c Binding Inflammatory bowel disease: an increased risk factor for neurologic complications Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis Diagnosis and Management of Multiple Sclerosis in Children Polyomaviruses and disease: is there more to know than viremia and viruria?

P2860

Q21285083-2B74B296-803B-4675-B47A-5A36A9E05006 Q22241416-B46C7A96-8086-4BCB-BC12-63CA5A50BEC1 Q24187571-A3C25BB3-D90E-4B64-8F7D-3204FD94F8B4 Q24194423-9F73158A-1C31-422F-824E-2ABA1B941F4B Q24202108-D3254FDC-EC76-4606-B935-C485A36AEA26 Q26745782-D21EF0BA-80A1-4987-B859-BC3E3AD58601 Q26748229-824B58F3-2603-4AC4-B0D3-0BA3972C88C8 Q26766172-D310059C-C735-480C-8F60-334CFA370325 Q26768259-C69663AF-BAD4-4EC2-8C7D-54AADEA92E81 Q26770388-18393A60-0526-4347-A0BE-3002E2193207 Q26776157-9957F3F5-77C2-4D3F-87EE-2571CD1471AA Q26776234-3E8DAC78-2287-4D90-84C0-AB4D472CD42D Q26776236-73DBA04D-B208-491E-B18C-470F15FA504B Q26777329-8C1C9D2C-E0B3-4655-A829-39BCFEC2201B Q26777686-7EE361BD-6353-4010-804F-D50B2C06B1AC Q26780412-B0F0BE8F-517A-41C6-A58B-1A5F2AFD3294 Q26781330-B614376A-C963-406D-846B-B9F73C864AE2 Q26784139-E4E9C800-8A26-4C62-B091-F01DF5BBDD3B Q26797993-DDF52561-F007-4A62-8189-7AC3FFDF9849 Q26798434-E6B7C7F4-DD9A-4B6E-B788-4CD76633E926 Q26822611-97F84ED4-1692-41EC-BA5B-3490F804BFE2 Q26822941-327C3EDD-72C3-489C-B265-ED68EBC41C75 Q26826930-F69B8957-DE5B-4938-BFEC-7436A0213D64 Q26827467-A6B2803B-4058-4601-BEFC-58233A4D8FE0 Q26852060-ABE7C14A-1791-43C2-A134-155631C4DE32 Q26859307-7BAC0958-F74A-4520-A431-86C8B68D3DF1 Q26999417-A021081A-E0DF-477E-96F7-2726AAC676A9 Q26999705-E42B2CEF-79E8-4A4E-8DA5-9A9A2B40A944 Q27001711-DB589A0B-E797-47CD-ADF9-C061FF220D0D Q27009769-DD0CE81C-1492-4572-8C18-A21425BDEC98 Q27012726-DDBA3BAB-A317-48D2-AA58-1CE1E24A550F Q27016148-2A886140-07F3-4B24-B4D8-0BD887B7ECFC Q27021612-930ED8EC-C18B-4266-8C08-5A9FD38E7E3F Q27025933-BF28D066-333D-44BB-B6DA-64F75C07A025 Q27678593-844FD7E9-4775-4C78-8499-0AB2C29B9751 Q27690759-AA5892ED-E926-4C0B-84C8-11DE3E17051D Q28066677-59A5A6EF-F8FC-43A6-A091-1687B1259036 Q28067760-A35182F4-4E97-4758-9BB7-4E2F1E3FB25A Q28069571-476D3062-E256-4B96-98AB-7DB3B3357A12 Q28081350-D5A62EAE-E018-4536-89C1-6B9F513954B9

P2860

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

http://www.wikidata.org/entity/Q34275329

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@ast

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@en

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@nl

type

label

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@ast

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@en

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@nl

prefLabel

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@ast

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@en

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@nl

P1433

Q34275329-8D95FB65-F6BF-48A4-9E04-A00CCEBAAFD8

P1476

Q34275329-0B6538DE-E76E-4744-B2CE-6D00BDB648D6

P2093

Q34275329-0ABEF463-0956-44A1-9DDC-B7FDA0009B60

Q34275329-144761AB-912B-4657-8EBD-646BA541E079

Q34275329-383EA2FA-1E56-41C4-B410-233333114EC0

Q34275329-5A044E79-50A0-47FE-95EF-8B308E202898

Q34275329-7CF57FDE-2A10-4323-922E-A04FCBFABA91

Q34275329-9D406A87-C669-4F1C-AB95-AD8D651D125A

Q34275329-CCE59B89-F01C-4913-96A4-C85609802EBE

Q34275329-E832110F-E802-43DB-A79B-7DB9DA0FAF40

Q34275329-F1D9E690-793F-41AF-892E-C72B3086C869

Q34275329-F8497CDC-E04A-4EA4-963E-84EE79E776F3

P304

Q34275329-246C1C4A-C0BE-4E96-8DDF-234D98AF02A9

P31

Q34275329-92B0F1BE-84E9-4D53-AFD5-53340D65755D

P356

Q34275329-26DC662F-43A9-4BB5-AE98-717FC3C785FB

P407

Q34275329-62908E7C-73DF-4699-895C-6CEAB8EA07EC

P433

Q34275329-F073DD67-2266-4129-80D8-C6E79CD2CD53

P478

Q34275329-C4DD66AB-8C89-4C2E-B5EB-E8C753916780

P577

Q34275329-0BE8DD8E-0F2A-42EB-97BA-6E4A7CBECE8E

P698

Q34275329-82FDC6CE-389B-4074-AF04-F8B08F04E1A6

P921

Q34275329-DA1EB6B6-515A-490A-BFCC-8BC56AC3AA37

P356

P1433

The New England Journal of Medicine

P1476

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@en

P2093

Alfred Sandrock

http://www.w3.org/2001/XMLSchema#string

Amy Natarajan

http://www.w3.org/2001/XMLSchema#string

Carmen Bozic

http://www.w3.org/2001/XMLSchema#string

Christophe Hotermans

http://www.w3.org/2001/XMLSchema#string

Gary Bloomgren

http://www.w3.org/2001/XMLSchema#string

James V Scanlon

http://www.w3.org/2001/XMLSchema#string

Meena Subramanyam

http://www.w3.org/2001/XMLSchema#string

Sandra Richman

http://www.w3.org/2001/XMLSchema#string

Sophia Lee

http://www.w3.org/2001/XMLSchema#string

Susan Goelz

http://www.w3.org/2001/XMLSchema#string

P304

1870-1880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1107829

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22591293

http://www.w3.org/2001/XMLSchema#string

P921

progressive multifocal leukoencephalopathy